COVID-19 | Brian Pinker, the first patient to receive the AstraZeneca vaccine in the UK

The United Kingdom inoculated the world’s first patient with the coronavirus vaccine from pharmaceutical giant AstraZeneca and the University of Oxford this Monday.

Brian Pinker, 82, was vaccinated at Oxford and said he was proud to get the vaccine and felt nothing.

“The vaccine means everything to me, that is, from my point of view it is the only way to return to normal life. This virus is terrible, right?” said.

Health Secretary Matt Hancock said he was delighted with the launch of the country’s second approved coronavirus vaccine, which he said was a “consecration for British science.”

“This is a pivotal moment in our fight against this horrible virus and I hope it provides renewed hope to everyone that an end to this pandemic is in sight,” Hancock said in a statement.

The country secured 100 million doses of the vaccine, which is much cheaper and easier to store than Pfizer’s mRNA vaccine, which the UK began distributing to the population in December, becoming the first country to approve it.

More than 500,000 doses will be available on Monday as the UK rushes to vaccinate the most vulnerable against the new coronavirus.

Hancock said more than a million vaccines had been administered as of early January and he hopes to increase that number significantly in the next month.

The country has registered 50,000 new cases a day for several days, as the new, most transmissible variant of the virus spreads through the country.

Despite the vaccine deployment, the COVID-19 crisis continues to worsen as infections rise.

The opposition leader, Keir Starmer, has called for a national confinement due to the increase in cases, something that the government does not rule out, Hancock told Sky News.

Some experts have criticized the UK’s strategy stating that they need to focus on working to reduce infections rather than relying on future vaccinations to solve the crisis.

Second vaccine approved in December

The UK drug regulator approved AstraZeneca’s vaccine for emergency use on December 30, becoming the first country to give the company’s vaccine the go-ahead.

The UK has more than 730 vaccination centers and is looking to increase that number to more than 1,000.

The Oxford vaccine is based on a weakened, harmless adenovirus that often causes the common cold in chimpanzees.

Despite some dosing errors, the vaccine was found to be up to 90% effective in clinical trials, AstraZeneca and Oxford said in November, based on interim data from phase three of the trials.